PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts. Show more

Location: 321 Harrison Avenue, Boston, MA, 02118, United States | Website: https://pepgen.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

44.17M

52 Wk Range

$0.88 - $19.30

Previous Close

$1.35

Open

$1.36

Volume

330,399

Day Range

$1.31 - $1.41

Enterprise Value

-43.19M

Cash

97.78M

Avg Qtr Burn

-20.69M

Insider Ownership

0.27%

Institutional Own.

95.95%

Qtr Updated

03/31/25